Our Commitment to ESG Transparency
BioMarin is committed to transparency into environment, social and governance (ESG) activities at our company. In 2022, we took several additional actions to advance our commitment to ESG issues, including:
- Forming an internal cross-functional team of organizational leaders to respond to and address stakeholder feedback received on all ESG issues. The cross-functional ESG Core Team is overseen by an ESG Executive Steering Committee comprised of top executives, including our chief company officers for legal, compliance, finance/investor relations, technical operations, people and communications. In addition, the BioMarin Board of Directors’ Corporate Governance Nominating Committee provides further oversight of all ESG activities.
- Hiring an independent consulting firm with expertise in ESG risk management and disclosure to provide technical advice to the cross-functional team.
- Disclosing additional ESG information on BioMarin.com.
- Completing an MSCI gap analysis.
- Completing a limited materiality assessment, which identified the ESG topics most important to our business and stakeholders.
- Compiling and analyzing information deemed financially material by SASB’s Biotechnology & Pharmaceuticals, Sustainability Accounting Standard, Version 2018-10, and published a SASB index on BioMarin.com with hyperlinks to more detailed corporate responsibility narratives included throughout our website.
From this work, BioMarin plans to complete the following additional actions by 2025:
- Monitor changes in MSCI score and gauge investor feedback as more information is disclosed, and report back on progress.
- Publish a formal ESG report.
- Develop and implement additional ESG goals and initiatives.
View our SASB Index to learn more
